Dasatinib News and Research

RSS
Dasatinib is an orally bioavailable synthetic small molecule-inhibitor of SRC-family protein-tyrosine kinases. Dasatinib binds to and inhibits the growth-promoting activities of these kinases. Apparently because of its less stringent binding affinity for the BCR-ABL kinase, dasatinib has been shown to overcome the resistance to imatinib of chronic myeloid leukemia (CML) cells harboring BCR-ABL kinase domain point mutations. SRC-family protein-tyrosine kinases interact with variety of cell-surface receptors and participate in intracellular signal transduction pathways; tumorigenic forms can occur through altered regulation or expression of the endogenous protein and by way of virally-encoded kinase genes.
EMA adopts positive opinion for Pfizer’s bosutinib conditional approval in the EU

EMA adopts positive opinion for Pfizer’s bosutinib conditional approval in the EU

NEDD9 gene controls growth of progenitor cells that give rise to breast tumors

NEDD9 gene controls growth of progenitor cells that give rise to breast tumors

Ponatinib thwarts T315I gene mutation in chronic myeloid leukemia

Ponatinib thwarts T315I gene mutation in chronic myeloid leukemia

Pfizer receives FDA approval for BOSULIF to treat Ph+ chronic myelogenous leukemia

Pfizer receives FDA approval for BOSULIF to treat Ph+ chronic myelogenous leukemia

FDA approves Bosulif to treat chronic myelogenous leukemia

FDA approves Bosulif to treat chronic myelogenous leukemia

ARIAD initiates multi-center ponatinib Phase 1/2 clinical trial for CML in Japan

ARIAD initiates multi-center ponatinib Phase 1/2 clinical trial for CML in Japan

Scientists identify new genetic alterations underlying high-risk subtype of ALL

Scientists identify new genetic alterations underlying high-risk subtype of ALL

ARIAD Pharmaceuticals commences ponatinib Phase 3 trial in newly diagnosed CML

ARIAD Pharmaceuticals commences ponatinib Phase 3 trial in newly diagnosed CML

Updated data from ARIAD’s ponatinib pivotal trial on CML or Ph+ ALL

Updated data from ARIAD’s ponatinib pivotal trial on CML or Ph+ ALL

Otsuka, Bristol-Myers Squibb announce six-year data from SPRYCEL Phase 3 trial on CP-CML

Otsuka, Bristol-Myers Squibb announce six-year data from SPRYCEL Phase 3 trial on CP-CML

caprotec's CCMS technology identifies novel co-targets of three anti-cancer drugs

caprotec's CCMS technology identifies novel co-targets of three anti-cancer drugs

CytRx reports net loss of $0.6 million for third quarter 2011

CytRx reports net loss of $0.6 million for third quarter 2011

PKM2 enzyme has important non-metabolic functions in cancer formation

PKM2 enzyme has important non-metabolic functions in cancer formation

ARIAD reports net income of $13.9 million for third quarter 2011

ARIAD reports net income of $13.9 million for third quarter 2011

New library for development of targeted cancer drugs

New library for development of targeted cancer drugs

EMA accepts Pfizer's regulatory submissions of two investigational cancer drugs for review

EMA accepts Pfizer's regulatory submissions of two investigational cancer drugs for review

Taxoxifen combined with dasatinib reverses chemo-resistance in breast cancer cells

Taxoxifen combined with dasatinib reverses chemo-resistance in breast cancer cells

Health Canada approves SPRYCEL as first-line treatment for life-threatening blood cancer

Health Canada approves SPRYCEL as first-line treatment for life-threatening blood cancer

Medco announces new offerings within Advanced Oncology Solutions

Medco announces new offerings within Advanced Oncology Solutions

Positive preliminary results from CytRx bafetinib Phase 2 trial for relapsed B-cell chronic lymphocytic leukemia

Positive preliminary results from CytRx bafetinib Phase 2 trial for relapsed B-cell chronic lymphocytic leukemia